Why Edgewise Therapeutics Stock Popped This Week

1 month ago 18

Eric Volkman, The Motley Fool

Fri, May 2, 2025, 4:07 PM 2 min read

In This Article:

  • A researcher initiated sum of the banal with a bargain recommendation.

  • He feels its terms could scope $41 per share.

On Thursday, an expert launched sum of Edgewise Therapeutics (NASDAQ: EWTX) stock, and the marketplace took announcement successful a bully way. On the backmost of his bullish presumption of the company, according to information compiled by S&P Global Market Intelligence, its stock terms vaulted astir 14% higher crossed the week.

That nonrecreational was Guggenheim's Debjit Chattopadhyay, who initiated his Edgewise Therapeutics sum with a bargain recommendation, and terms people of $41 per share. That's good much than treble the biotech stock's astir caller closing price, conscionable shy of $17.

Where to put $1,000 close now? Our expert squad conscionable revealed what they judge are the 10 champion stocks to bargain close now. Continue »

Two radical   successful  achromatic  laboratory  coats looking astatine  a machine  display.

Image source: Getty Images.

According to reports, Chattopadhyay wrote successful his inaugural probe enactment connected Edgewise that with its charismatic endeavor worth (EV), combined with rather a promising pipeline, the company's banal has important upside potential.

That EV presently stands astatine implicit $1 billion, the expert pointed out, and it has not 1 but 2 promising improvement programs. The archetypal is EDG-7500, a attraction targeting obstructive and nonobstructive hypertrophic cardiomyopathy, a bosom disorder, and the 2nd is Duchenne muscular dystrophy cause sevasemten. Clinical proceedings results should travel successful for some wrong the adjacent year.

Given each that, Edgewise is successful a amended presumption than galore different biotechs to succeed. We should ever carnivore successful caput with specified companies, however, that overmuch depends connected their pipelines. If experimental drugs bash good successful the laboratory and yet triumph regulatory approval, the developer could beryllium rather the victor connected the banal market. However, the other is usually existent if a pipeline cause flops.

Before you bargain banal successful Edgewise Therapeutics, see this:

The Motley Fool Stock Advisor expert squad conscionable identified what they judge are the 10 champion stocks for investors to bargain now… and Edgewise Therapeutics wasn’t 1 of them. The 10 stocks that made the chopped could nutrient monster returns successful the coming years.

Consider when Netflix made this database connected December 17, 2004... if you invested $1,000 astatine the clip of our recommendation, you’d person $611,271!* Or when Nvidia made this database connected April 15, 2005... if you invested $1,000 astatine the clip of our recommendation, you’d person $684,068!*

Now, it’s worthy noting Stock Advisor’s full mean instrumentality is 889% — a market-crushing outperformance compared to 162% for the S&P 500. Don’t miss retired connected the latest apical 10 list, disposable erstwhile you join Stock Advisor.

See the 10 stocks »

Read Entire Article